• Vaccine Name: MVvac2-CoV-solS
• Target Pathogen: MERS-CoV
• Target Disease: Middle East Respiratory Syndrome (MERS)
• Type: Recombinant vector vaccine
• Status: Licensed
• Host Species for Licensed Use: None
• Antigen: truncated soluble S protein (Malczyk et al., 2015)
• Immunization Route: Intraperitoneal injection (i.p.)
• Description: MVs expressing a soluble, truncated version of spike glycoprotein of MERS-CoV in its full-length cloned into vaccine strain MVvac2 genome and rescued (Malczyk et al., 2015)

Mouse Response

• Host Strain: IFNAR−/−-CD46Ge
• Vaccination Protocol: inoculated intraperitoneally (i.p.) with 1 × 105 TCID50 of recombinant MV(Malczyk et al., 2015)
• Immune Response: Immune Response Description: increased viral neutralizing titers, increased CD8+ T cells with low CFSE (Malczyk et al., 2015)
• Challenge Protocol: Challenge Protocol: immunized mice were transduced intranasally (i.n.) on day 63 with 20 μl of an adenovirus vector encoding human DPP4 and mCherry with a final titer of 2.5 × 108 PFU per inoculum (AdV-hDPP4; ViraQuest Inc.) and challenged i.n. with 20 μl of MERS-CoV at a final titer of 7 × 104 TCID50 on day 68.(Malczyk et al., 2015)
• Efficacy: decreased viral loads, even accounting for fraction of mice where transduction of MERS-CoV failed (~30%) (Malczyk et al., 2015